Haemonetics Corporation Financial Statements (HAE)
|
|
|
|
Report date
|
|
|
22.05.2014 |
22.05.2015 |
01.06.2016 |
24.05.2017 |
23.05.2018 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
938.5 |
910.4 |
908.8 |
886.1 |
903.9 |
|
Operating Income, bln rub |
|
|
47.3 |
40.5 |
-43.9 |
-19.4 |
56.2 |
|
EBITDA, bln rub |
? |
|
127.0 |
125.7 |
128.7 |
123.2 |
153.0 |
|
Net profit, bln rub |
? |
|
35.1 |
16.9 |
-55.6 |
-26.3 |
45.6 |
|
|
OCF, bln rub |
? |
|
139.5 |
127.2 |
121.9 |
159.7 |
220.4 |
|
CAPEX, bln rub |
? |
|
73.6 |
122.2 |
102.4 |
76.1 |
74.8 |
|
FCF, bln rub |
? |
|
65.9 |
4.96 |
19.5 |
83.6 |
145.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
|
OPEX, bln rub |
|
|
421.0 |
393.9 |
449.9 |
397.9 |
355.8 |
|
Cost of production, bln rub |
|
|
470.1 |
476.0 |
502.9 |
507.6 |
492.0 |
|
R&D, bln rub |
|
|
54.2 |
54.2 |
55.9 |
47.3 |
39.2 |
|
Interest expenses, bln rub |
|
|
10.9 |
9.38 |
9.47 |
8.10 |
4.53 |
|
|
Assets, bln rub |
|
|
1 521 |
1 483 |
1 317 |
1 239 |
1 237 |
|
Net Assets, bln rub |
? |
|
839.6 |
826.1 |
720.0 |
739.6 |
752.4 |
|
Debt, bln rub |
|
|
437.7 |
427.9 |
408.0 |
314.6 |
253.7 |
|
Cash, bln rub |
|
|
192.5 |
160.7 |
115.1 |
139.6 |
180.2 |
|
Net debt, bln rub |
|
|
245.2 |
267.2 |
292.9 |
175.1 |
73.5 |
|
|
Ordinary share price, rub |
|
|
32.6 |
44.9 |
35.0 |
40.6 |
|
|
Number of ordinary shares, mln |
|
|
51.6 |
51.5 |
50.9 |
51.5 |
52.8 |
|
|
Market cap, bln rub |
|
|
1 682 |
2 315 |
1 781 |
2 090 |
0 |
|
EV, bln rub |
? |
|
1 927 |
2 582 |
2 074 |
2 265 |
74 |
|
Book value, bln rub |
|
|
232 |
247 |
248 |
351 |
384 |
|
|
EPS, rub |
? |
|
0.68 |
0.33 |
-1.09 |
-0.51 |
0.86 |
|
FCF/share, rub |
|
|
1.28 |
0.10 |
0.38 |
1.62 |
2.76 |
|
BV/share, rub |
|
|
4.49 |
4.80 |
4.87 |
6.82 |
7.29 |
|
|
EBITDA margin, % |
? |
|
13.5% |
13.8% |
14.2% |
13.9% |
16.9% |
|
Net margin, % |
? |
|
3.75% |
1.86% |
-6.12% |
-2.96% |
5.04% |
|
FCF yield, % |
? |
|
3.92% |
0.21% |
1.09% |
4.00% |
|
|
ROE, % |
? |
|
4.19% |
2.05% |
-7.73% |
-3.55% |
6.06% |
|
ROA, % |
? |
|
2.31% |
1.14% |
-4.22% |
-2.12% |
3.68% |
|
|
P/E |
? |
|
47.9 |
137.0 |
-32.0 |
-79.5 |
0.00 |
|
P/FCF |
|
|
25.5 |
466.9 |
91.5 |
25.0 |
0.00 |
|
P/S |
? |
|
1.79 |
2.54 |
1.96 |
2.36 |
0.00 |
|
P/BV |
? |
|
7.26 |
9.36 |
7.19 |
5.95 |
0.00 |
|
EV/EBITDA |
? |
|
15.2 |
20.5 |
16.1 |
18.4 |
0.48 |
|
Debt/EBITDA |
|
|
1.93 |
2.13 |
2.28 |
1.42 |
0.48 |
|
|
R&D/CAPEX, % |
|
|
73.6% |
44.3% |
54.6% |
62.1% |
52.4% |
|
|
CAPEX/Revenue, % |
|
|
7.85% |
13.4% |
11.3% |
8.59% |
8.27% |
|
| Haemonetics Corporation shareholders |
